Brief Report
Volume 08:05, 2025

Journal of Biomedical and Pharmaceutical Sciences

ISSN: 2952-8100

Open Access

Beyond Symptoms: Novel Strategies For Neurodegenerative Disorders

Samuel D. Okoye*

Department of Pharmacology and Toxicology, University of Lagos, Nigeria

Introduction

Neurodegenerative disorders represent a significant and growing challenge to global health, impacting millions worldwide and imposing immense personal and societal burdens. The complex pathological mechanisms underlying these conditions necessitate the development of novel and effective therapeutic strategies. This exploration delves into the cutting edge of research, focusing on innovative approaches designed to address the root causes of neurodegeneration rather than merely alleviating symptoms.

One prominent area of investigation involves the exploration of innovative therapeutic strategies for neurodegenerative disorders, emphasizing novel drug targets and delivery systems. This includes advancements in gene therapy, cell-based therapies, and the repurposing of existing drugs, with a focus on addressing the underlying pathology rather than just symptom management [1].

Further research highlights the potential of targeting neuroinflammation as a therapeutic avenue for conditions like Alzheimer's and Parkinson's disease. This involves discussing various anti-inflammatory agents and their mechanisms of action in preclinical and clinical settings, while also acknowledging the associated challenges and opportunities [2].

The intricate relationship between the gut microbiota and the brain has also emerged as a critical area of study. Investigations examine the role of the gut microbiota in the pathogenesis of neurodegenerative disorders and explore microbiome-targeted therapies, including the use of probiotics, prebiotics, and fecal microbiota transplantation for managing diseases like Parkinson's, with the gut-brain axis being a central theme [3].

In parallel, gene therapy approaches are being developed for treating genetic forms of neurodegenerative diseases. This involves discussing the challenges of gene delivery to the central nervous system and highlighting successful preclinical and early clinical trial outcomes for conditions such as Huntington's disease [4].

The development of small molecule inhibitors targeting protein aggregation in neurodegenerative diseases is another active field. Strategies aim to inhibit the formation and propagation of amyloid-beta and alpha-synuclein aggregates, which are crucial in Alzheimer's and Parkinson's diseases, respectively [5].

The utilization of exosomes as nanocarriers for therapeutic delivery across the blood-brain barrier in neurodegenerative diseases is being explored. The focus is on engineered exosomes for the targeted delivery of drugs and nucleic acids [6].

Furthermore, induced pluripotent stem cells (iPSCs) are being investigated for disease modeling and cell-based therapies in neurodegenerative disorders. Advancements in generating patient-specific neurons and glial cells for regenerative medicine approaches are particularly noteworthy [7].

The review of repurposed drugs showing promise in treating neurodegenerative conditions offers an accelerated path to clinical application. This includes discussing drugs originally developed for other diseases that are now being explored for their neuroprotective effects [8].

Finally, the development and application of antisense oligonucleotides (ASOs) as a therapeutic strategy for genetic neurodegenerative disorders are being examined. This involves detailing how ASOs can modulate gene expression to reduce the production of toxic proteins [9]. The potential of targeting protein degradation pathways, such as the ubiquitin-proteasome system, as a therapeutic approach for neurodegenerative diseases is also under investigation, involving the modulation of cellular machinery responsible for clearing misfolded or aggregated proteins [10].

Description

The landscape of neurodegenerative disorder treatment is undergoing a profound transformation, shifting from symptom management to addressing the fundamental pathological processes. A key development is the exploration of innovative therapeutic strategies, which encompasses novel drug targets and sophisticated delivery systems. These advancements include the promising fields of gene therapy and cell-based therapies, alongside the strategic repurposing of existing pharmaceuticals, all aimed at tackling the root causes of these debilitating conditions [1].

Neuroinflammation has been identified as a critical contributor to the progression of neurodegenerative diseases such as Alzheimer's and Parkinson's. Consequently, targeting this inflammatory response with various anti-inflammatory agents and understanding their mechanisms of action are crucial. While preclinical and clinical studies are yielding promising results, significant challenges and opportunities remain in this therapeutic avenue [2].

The gut-brain axis, mediated by the gut microbiota, is increasingly recognized for its role in neurodegenerative pathogenesis. Research into microbiome-targeted therapies, including probiotics, prebiotics, and fecal microbiota transplantation, offers a novel approach to managing conditions like Parkinson's disease, highlighting the intricate connection between gut health and neurological function [3].

For neurodegenerative diseases with a clear genetic component, gene therapy presents a compelling treatment option. Overcoming the hurdles of delivering therapeutic genes effectively to the central nervous system is a primary focus, with ongoing efforts to refine techniques and translate successful preclinical findings

into clinical applications, particularly for diseases like Huntington's [4].

Protein aggregation is a hallmark of many neurodegenerative disorders. The development of small molecule inhibitors designed to prevent the formation and spread of toxic protein aggregates, such as amyloid-beta and alpha-synuclein, is a significant area of research for Alzheimer's and Parkinson's diseases, respectively [5].

The blood-brain barrier presents a formidable obstacle for drug delivery to the central nervous system. Exosomes, as natural nanocarriers, are being investigated for their potential to encapsulate and deliver therapeutic agents across this barrier. Research is particularly focused on engineering exosomes for the precise delivery of drugs and nucleic acids in the context of neurodegenerative diseases [6].

Induced pluripotent stem cells (iPSCs) are revolutionizing disease modeling and therapeutic development for neurodegenerative conditions. The ability to generate patient-specific neurons and glial cells from iPSCs opens up new avenues for regenerative medicine and a deeper understanding of disease mechanisms [7].

Drug repurposing offers a more rapid and cost-effective pathway to developing new treatments for neurodegenerative diseases. By investigating drugs initially developed for other conditions, researchers are identifying compounds with potential neuroprotective effects and exploring their clinical applications [8].

Antisense oligonucleotides (ASOs) represent a targeted therapeutic strategy for genetic neurodegenerative disorders. These molecules are designed to precisely modulate gene expression, thereby reducing the production of harmful proteins implicated in disease progression [9].

Finally, therapeutic interventions aimed at modulating protein degradation pathways, such as the ubiquitin-proteasome system, are gaining traction. By influencing the cellular machinery responsible for clearing misfolded or aggregated proteins, researchers hope to mitigate the toxic accumulation that drives neurodegeneration [10].

Conclusion

This collection of research highlights the evolving strategies in combating neurodegenerative disorders, moving beyond symptom management to target underlying pathologies. Key therapeutic avenues explored include novel drug targets, advanced delivery systems, gene therapy, cell-based treatments, and the repurposing of existing drugs. Neuroinflammation is identified as a significant factor, with therapies aimed at reducing inflammatory responses. The gut-brain axis and microbiome modulation are also emerging as critical areas for intervention. Furthermore, research focuses on inhibiting protein aggregation, utilizing exosomes for drug delivery, and employing induced pluripotent stem cells for disease modeling and regenerative medicine. Antisense oligonucleotides and modulation of protein degradation pathways are also presented as promising strategies for treating genetic and protein-related neurodegenerative conditions. These diverse approaches collectively aim to offer more effective and targeted treatments for these complex diseases.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Ojo, Olusegun A., Olatunji, Olusola S., Adedokun, Oladapo D.. "Novel Therapeutic Approaches for Neurodegenerative Disorders." *J Biomed Pharm Sci* 10 (2023):1-15.
2. Eichmann, S., Heneka, M. T., Golenbock, D. T.. "Targeting Neuroinflammation in Neurodegenerative Diseases: A Promising Therapeutic Strategy." *Int J Mol Sci* 23 (2022):23(14):7811.
3. Cryan, John F., O'Riordan, Kenneth J., Sandhu, K., Ryan, Aoife. "The Gut Microbiota-Brain Axis in Neurodegenerative Diseases: Therapeutic Strategies." *Cell Host & Microbe* 29 (2021):29(3):328-340.e5.
4. Yechikhov, O., Schopfer, L. M., Harding, J. J.. "Gene Therapy for Neurodegenerative Diseases." *Hum Gene Ther* 34 (2023):34(3-4):123-135.
5. He, X., Chen, Y., Wang, J.. "Small Molecules Targeting Protein Aggregation in Neurodegenerative Diseases." *ACS Chem Neurosci* 12 (2021):12(7):1135-1149.
6. Lener, M. P., Boraschi, D., Tagliamonte, M.. "Exosomes as Nanocarriers for Therapeutic Delivery Across the Blood-Brain Barrier in Neurodegenerative Diseases." *Nanomedicine: NBM* 43 (2022):43:102570.
7. Kuhn, G., Schwartz, J., Gage, F. H.. "Induced Pluripotent Stem Cells in Neurodegenerative Disease Research and Therapy." *Trends in Neurosciences* 44 (2021):44(10):801-813.
8. O'Connell, L., Egan, P., O'Mahony, S.. "Drug Repurposing for Neurodegenerative Diseases." *Expert Opin Ther Pat* 33 (2023):33(2):179-193.
9. Rizzo, A. M., Mazzini, L., Massaro, E.. "Antisense Oligonucleotides for Neurodegenerative Diseases." *Mol Ther Nucleic Acids* 27 (2022):27:741-755.
10. Xie, Y., Li, H., Zhang, W.. "Modulating Protein Degradation Pathways for Neurodegenerative Disease Therapy." *Cell Death & Disease* 14 (2023):14(5):293.

How to cite this article: Okoye, Samuel D.. "Beyond Symptoms: Novel Strategies For Neurodegenerative Disorders." *J Biomed Pharm Sci* 08 (2025):538.

Address for Correspondence: Samuel, D. Okoye, Department of Pharmacology and Toxicology, University of Lagos, Nigeria, E-mail: s.okoye@unilagrty.edu.ng

Received: 01-Sep-2025, Manuscript No. jbps-26-184407; **Editor assigned:** 03-Sep-2025, PreQC No. P-184407; **Reviewed:** 17-Sep-2025, QC No. Q-184407; **Revised:** 22-Sep-2025, Manuscript No. R-184407; **Published:** 29-Sep-2025, DOI: 10.37421/2952-8100.2025.8.538